-
2026-01-16
GenSci Unveils 7 Innovative Pipeline at JPM 2026Learn More
-
2025-12-23
GenSci Partners with Leading AI Company Partex AI to Accelerate Drug Development and Global CommercializationLearn More
-
2025-12-16
GenSci Secures Up to $1.365B in Global ex-China Licensing Deal for GS-098(YB-101) with RTW InvestmentsLearn More
-
2025-12-02
A Leading Force in Innovation:
GenSci Earns Dual Recognition as Global Innovator & 2025 China Pharma Top 100Learn More
-
2025-09-18
GenSci Partners with Allergy Immunotherapy Leader ALK to Bring Innovative AIT Solutions for Chinese PatientsLearn More
-
2025-07-04
Firsekibart Approved with 87% Reduction in Gout Recurrence Over 6 MonthsLearn More
-
2025-06-18
NMPA Approves New Indication Clinical Trial of Megestrol Acetate Oral SuspensionLearn More
-
2025-03-21
Global R&D Milestone: Clinical Trial of GenSci120 Will Be Launched in the U.S.Learn More
-
2025-03-07
Episil® Launched in China: A Breakthrough Solution for Oral MucositisLearn More
-
2025-02-20
GenSci Submits Another Blockbuster Product for Market ApprovalLearn More
-
2025-02-10
Clinical Trial Commencement of GenSci120 Injection ApprovedLearn More
-
2025-01-22
GenSci Showcases the Latest R&D Achievements at J.P. MorganLearn More
-
2025-01-17
NMPA Approves the PD-1 agonist GenSci120 for Clinical Trials CommencementLearn More